Cargando…
Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
Autores principales: | Feher, Michael, Joy, Mark, Munro, Neil, Hinton, William, Williams, John, de Lusignan, Simon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590506/ https://www.ncbi.nlm.nih.gov/pubmed/34802683 http://dx.doi.org/10.1016/j.atherosclerosis.2021.11.012 |
Ejemplares similares
-
Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol
por: Hinton, William, et al.
Publicado: (2018) -
Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
por: Hinton, William, et al.
Publicado: (2019) -
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)
por: Feher, Michael, et al.
Publicado: (2022) -
Real world and hyper reality
por: Gautret, Philippe, et al.
Publicado: (2021) -
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
por: McGovern, Andrew, et al.
Publicado: (2017)